Make your money go further for just 25p per day

Tristel gains key approval in China

Tristel logo on purple background
Tristel has its sights firmly set on China as a crucial market for long-term revenue growth. The approval of its Duo High-Level disinfectant is therefore very good news which should spark revenue growth.

In brief

Medical device specialist, Tristel (LON: TSTL) has gained approval for two of its specialist infection prevention products in Asia. The Duo High-Level disinfectant has been approved in China by the Shanghai Centre for Disease Control and Prevention and the Sporicidal Wipe has been approved in South Korea by the Korean Ministry of Food and Drug Safety.

The detail

Duo is one of the products Tristel has been attempting to launch in the US, without much success to date. Regulatory approval in China has taken a fraction of the time and the market presents a big opportunity for expansion. When Tristel released its interim results in February, management laid out plans to “concentrate our efforts on selling our consumable medical device disinfectants directly to hospitals” in China. The approval of Duo is a major step towards that goal.

The South Korea approval “highlights Tristel’s regulatory and technical capabilities,” according to broker finnCap. The product has been approved as a drug…

Sign up and read the full article

Register to continue reading this article.

Get FREE access now

Already a member? Login

Have your say

Log in or register to view or add comments.

For access to the top news and insights from the investment world


Become a Champion Investor for as little as £3.20 per report or get a year's worth of money-making analysis for just £90.


More on Tristel

Portfolio Flash News: April

30/04/2019 · Portfolio Flash News

It’s not always easy to keep track of your investments. Sometimes big news gets hidden in…

Investor’s Champion podcast: ISA time

03/04/2019 · Podcasts
It’s ISA time. With just two days to go before the ISA deadline, it’s a good…

Tristel gains key approval in China

01/04/2019 · Portfolio Flash News
Tristel has its sights firmly set on China as a crucial market for long-term revenue growth.…

Tristel looks to China for more growth

13/03/2019 · Portfolio

The value of Tristel’s medical device decontamination products are highlighted by the fact that the company…

6 quality AIM shares for your portfolio

15/10/2015 · News & Insights

Our Blog this week has featured results and updates from a number of wonderful small…

More Portfolio Flash News

Diageo targets teetotallers

07/08/2019 · Diageo PLC

Moneysupermarket: energy price cap highlights need for comparison

07/08/2019 ·

Walt Disney misses expectations

07/08/2019 · Walt Disney